GRI Bio Inc. has announced positive interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis $(IPF.UK)$. The Independent Data Monitoring Committee has recommended the continuation of the study as no safety concerns were identified in the interim analysis of the first 24 patients. GRI-0621, a small molecule RAR-βɣ dual agonist, is being investigated for its potential to inhibit Type 1 Invariant NKT cells, which may play a role in fibrotic diseases. Interim biomarker data from the study are expected in July 2025, with topline results anticipated in the third quarter of 2025. Currently, only two approved drugs for IPF exist, both with significant side effects and limited impact on patient survival.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.